Agilent Technologies Expands Blood Cancer Research Tools Ahead of Q4 Results

Agilent Technologies announced the launch of its SureSelect Cancer Research Pan Heme panel, a new assay aimed at tumor profiling in hematologic malignancies. Designed in collaboration with hematology specialists, the product supports genomic profiling across blood cancer research workflows. The release broadens the company's precision oncology offerings, extending its cancer portfolio from solid-tumor tools into blood cancer research.

The new panel integrates with Agilent's broader research toolkit, which includes CrossLab services, digital pathology assets, and recurring consumables. The company has focused on expanding these lines to build consistent revenue. According to company tracking, CrossLab services and consumables recently delivered more than 5% core growth, assisted by roughly 70% of post-warranty equipment transitioning to multiyear service agreements.

The product launch comes alongside several recent business developments, including the rollout of the 5987A mass selective detector and the completed purchase of digital pathology software firm Proscia. Additionally, in October 2026, Agilent partnered with the University of Chicago to create a Center of Excellence for Energy Materials Research, supplying mass spectrometry and spectroscopy tools to advance battery and energy storage studies.

Attention is also turning to Agilent's fourth-quarter fiscal 2026 earnings, scheduled for release after market close on Nov. 23. According to Zacks Consensus Estimates, fourth-quarter revenue is projected at $1.99 billion, representing a 6.7% increase from the prior-year period, while adjusted earnings per share are projected at $1.72, up 8.2%. In the third fiscal quarter, Agilent achieved 9% revenue expansion in China, driven in part by capital spending on semiconductor and AI-related equipment.

Financial performance has supported shares over recent periods, with Agilent recording a 19.72% gain over 90 days and a 26.68% advance year to date. Despite this momentum, valuation assessments from Simply Wall St present differing views. While a widely watched fair value benchmark stands at $181.05 compared to a recent close of $174.76, its price-to-earnings ratio of 34.2x trades at a premium to its calculated fair ratio of 27.2x. Furthermore, market risks such as potential tariffs and reduced spending from academic and government institutions could pressure margins.